AroCell lanserar ny hemsida
01 févr. 2019 07h32 HE
|
AroCell AB
Idag lanserar AroCell sin nya hemsida. Målet med den nya hemsidan är att underlätta för våra kunder, affärspartner och investerare att hitta relevant information om AroCell. Webbplatsen (arocell.com)...
AroCell tecknar distributörsavtal med Eurobio Scientific i Frankrike
20 déc. 2018 02h00 HE
|
AroCell AB
Arocell tillkännager idag att ett distributionsavtal har tecknats med det franska företaget Eurobio Scientific, för distribution av AroCell TK 210 ELISA i Frankrike och Schweiz. AroCell TK 210 ELISA...
AroCell signs distribution agreement with Eurobio Scientific in France
20 déc. 2018 02h00 HE
|
AroCell AB
AroCell AB (publ) announced today that a distribution agreement has been signed with the French company Eurobio Scientific, for distribution of AroCell TK 210 ELISA in France and Switzerland. AroCell...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
24 août 2018 07h50 HE
|
AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
30 mai 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, May 30, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
14 mai 2018 16h30 HE
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting
10 avr. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and...
eFFECTOR Announces Appointment of John W. Smither to its Board of Directors
23 mars 2018 14h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA
24 oct. 2017 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological...
Surefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in Mexico
20 mars 2017 06h00 HE
|
Surefire Medical, Inc.
WESTMINSTER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the...